The ERα coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Rokicki, Jerzy ^a   Das, Partha M ^a   Giltnane, Jennifer M ^b   Wansbury, Olivia ^c   Rimm, David L ^b   Howard, Beatrice A ^c   Jones, Frank E ^a  

^a Tulane University   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; GAMMA SECRETASE; HER4 INTRACELLULAR DOMAIN; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; STEROID RECEPTOR COACTIVATOR 1; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; ESTROGEN ACTIVITY; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE REPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MAMMARY GLAND; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; FEMALE; GENE EXPRESSION; GENETICS; METABOLISM; MOUSE; PREGNANCY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; TUMOR CELL LINE; UDDER;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; MICE; MICE, TRANSGENIC; PREGNANCY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 77953435123     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-150     Document Type: Article

References (23)

1. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003, 21:1973-1979. 10.1200/JCO.2003.09.099, 12743151.
2. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005, 23:1616-1622. 10.1200/JCO.2005.10.036, 15755967.
3. Guler G, Iliopoulos D, Guler N, Himmetoglu C, Hayran M, Huebner K. Wwox and Ap2γ Expression Levels Predict Tamoxifen Response. Clin Cancer Res 2007, 13:6115-6121. 10.1158/1078-0432.CCR-07-1282, 17947476.
4. Jones FE. HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:247-258. 10.1007/s10911-008-9076-6, 2442669, 18473151.
5. Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey A, Marrero L, Vadlamudi RK, Jones FE. Coregulation of estrogen receptor by estrogen-inducible ERBB4/HER4 establishes a growth promoting autocrine signal in breast cancer. Cancer Res 2006, 66:7991-7998. 10.1158/0008-5472.CAN-05-4397, 16912174.
6. Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE. The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res 2008, 68:6387-6395. 10.1158/0008-5472.CAN-08-0538, 2538429, 18676864.
7. Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI, Tovey S, Cooke TG, Bartlett JMS, Jones FE. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res 2006, 66:6412-6420. 10.1158/0008-5472.CAN-05-2368, 16778220.
8. Vidal GA, Naresh A, Marrero L, Jones FE. Presenilin-dependent γ-secretase processing regulates multiple ERBB4/HER4 activities. J Biol Chem 2005, 280:19777-19783. 10.1074/jbc.M412457200, 15746097.
9. Thor AD, Edgerton SM, Jones FE. Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. Am J Pathol 2009, 175:1802-1809. 10.2353/ajpath.2009.090204, 19808643.
10. Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Harkonen P, Joensuu H, Isola J, Elenius K. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 2005, 65:1384-1393. 10.1158/0008-5472.CAN-04-3150, 15735025.
11. Brisken C, Park S, Vass T, Lydon JP, O'Malley BW, Weinberg RA. A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc Natl Acad Sci USA 1998, 95:5076-5081. 10.1073/pnas.95.9.5076, 20216, 9560231.
12. Jones FE, Welte T, Fu X-Y, Stern DF. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J Cell Biol 1999, 147:77-87. 10.1083/jcb.147.1.77, 2164978, 10508857.
13. Long W, Wagner K-U, Lloyd KCK, Binart N, Shillingford JM, Hennighausen L, Jones FE. Impaired differentiation and lactational failure in ErbB4-deficient mammary glands identify ERBB4 as an obligate mediator of Stat5. Development 2003, 130:5257-5268. 10.1242/dev.00715, 12954715.
14. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA, Shyamala G, Conneely OM, O'Malley BW. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 1995, 9:2266-2278. 10.1101/gad.9.18.2266, 7557380.
15. Mallepell S, Krust A, Chambon P, Brisken C. Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci USA 2006, 103:2196-2201. 10.1073/pnas.0510974103, 1413744, 16452162.
16. Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci USA 2003, 100:9744-9749. 10.1073/pnas.1732707100, 187836, 12897242.
17. Tidcombe H, Jackson-Fisher A, Mathers K, Stern DF, Gassmann M, Golding JP. Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality. Proc Natl Acad Sci USA 2003, 100:8281-8286. 10.1073/pnas.1436402100, 166220, 12824469.
18. Aupperlee MD, Haslam SZ. Differential hormonal regulation and function of progesterone receptor isoforms in normal adult mouse mammary gland. Endocrinology 2007, 148:2290-2300. 10.1210/en.2006-1721, 17317767.
19. Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ, de Cremoux P, Stenvang J, Lykkesfeldt AE. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2008, 114:263-275. 10.1007/s10549-008-0011-8, 2764248, 18409071.
20. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002, 8:1323-1327. 10.1038/nm791, 12389040.
21. Rubin MA, Zerkowski MP, Camp RL, Kuefer R, Hofer MD, Chinnaiyan AM, Rimm DL. Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol 2004, 164:831-840. 1613273, 14982837.
22. Burow ME, Weldon CB, Tang Y, McLachlan JA, Beckman BS. Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens. J Steroid Biochem Mol Biol 2001, 78:409-418. 10.1016/S0960-0760(01)00117-0, 11738551.
23. Hodges LC, Cook JD, Lobenhofer EK, Li L, Bennett L, Bushel PR, Aldaz CM, Afshari CA, Walker CL. Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res 2003, 1:300-311.